Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curdin Conrad

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
Nature Communications|January 4, 2018
TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasisCurdin Conrad, Jeremy Di Domizio, Alessio Mylonas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn studyLars Iversen, Curdin Conrad, Liv Eidsmo, et al.
International Journal of Molecular Sciences|July 26, 2020
Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon SignatureRoberto Lande, Anna Mennella, Raffaella Palazzo, et al.
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
JCI Insight|January 12, 2023
Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosaceaAlessio Mylonas, Heike C Hawerkamp, Yichen Wang, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Cancer Research|August 2, 2012
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cellsCurdin Conrad, Josh Gregorio, Yi-Hong Wang, et al.
The Journal of Experimental Medicine|March 6, 2024
Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26Alessia Baldo, Jeremy Di Domizio, Ahmad Yatim, et al.
International Journal of Dermatology|June 19, 2026
Swiss Practice Recommendations for Chronic Prurigo Including Prurigo NodularisSimon M Mueller, Helmut Beltraminelli, Wolf-Henning Boehncke, et al.
Frontiers in Immunology|April 24, 2025
The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasisRoberto Lande, Anna Mennella, Raffaella Palazzo, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
Nature Communications|January 4, 2018
TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasisCurdin Conrad, Jeremy Di Domizio, Alessio Mylonas, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn studyLars Iversen, Curdin Conrad, Liv Eidsmo, et al.
International Journal of Molecular Sciences|July 26, 2020
Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon SignatureRoberto Lande, Anna Mennella, Raffaella Palazzo, et al.
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
JCI Insight|January 12, 2023
Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosaceaAlessio Mylonas, Heike C Hawerkamp, Yichen Wang, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Cancer Research|August 2, 2012
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cellsCurdin Conrad, Josh Gregorio, Yi-Hong Wang, et al.
The Journal of Experimental Medicine|March 6, 2024
Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26Alessia Baldo, Jeremy Di Domizio, Ahmad Yatim, et al.
International Journal of Dermatology|June 19, 2026
Swiss Practice Recommendations for Chronic Prurigo Including Prurigo NodularisSimon M Mueller, Helmut Beltraminelli, Wolf-Henning Boehncke, et al.
Frontiers in Immunology|April 24, 2025
The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasisRoberto Lande, Anna Mennella, Raffaella Palazzo, et al.
Pageof 12